Validating imaging biomarkers
New imaging biomarkers are helping radiology to play a greater role in new drug developments.
Oncology
A challenge for oncologists
‘The disease “cancer” is increasingly classified into sub-groups. Today, we are already dealing with a number of orphan diseases,’ says Professor Richard Greil MD, head of LIMCR at University Hospital Salzburg.
Cancer: How to cut costs without risking the patients
In a review article published Feb. 14 in The Lancet Oncology, Johns Hopkins experts identify three major sources of high cancer costs and argue that cancer doctors can likely reduce them without harm to patients.
Curie-Cancer and Servier continue joined cancer research
Curie-Cancer, the body which leads the Institut Curie's industry partner research activity, and Servier, today announce that they have renewed their partnership with the aim of identifying therapeutic targets for treating ‘triple negative’ breast cancers. The partnership will continue for a further three years.
NCBC to launch its International Delegate Program
The “State of Oncology 2013” report by the International Prevention Research Institute [IPRI] warns that the global number of new cancer cases will have doubled between 2008 and 2030.
Collaborate – or face oblivion
Partnerships are at the top of the agenda for RSNA 2013. To meet current and emerging challenges, “we need internal partnerships within radiology and external ones with our clinical peers as well as with our patients,” outlined Sarah S. Donaldson, MD in her opening address of the 99th RSNA Scientific Assembly and Annual Meeting.
Article • MEDICA 2013
EndoMagnetics brings nanomedicine to breast cancer
It looks like a drug, it is injected in patients like a drug, but its acts like a medical device. Welcome to the new world of nanomedicine.
Article • MEDICA 2013
Genetically targeted medicine forges ahead
Healthcare is undergoing a major change set to offer a real prospect of far more genetically targeted treatments, according a leading human geneticist Sir John Burn, Professor of Clinical Genetics at Newcastle University, England.
Despite population decrease, in 2020 cancer case will increase
In the country’s first scientific study to correlate the demographic changes and frequency of tumorous diseases, demographic changes have led scientists to forecast a significant increase in the number of cancerous diseases in coming years.
EU regulation progresses on clinical trials
Along with others, Germany has unanimously welcomed the revision of the EU directive on clinical trials. The change from mere guideline into a regulation valid in all member states, specifically aimed at making it easier to carry out multinational studies, is particularly welcomed, Bettina Döbereiner reports
European nanomedicine research
Cancer diagnostics - Nanotechnology is currently being used in oncology to improve early tumour detection, imaging procedures and targeting of cancer therapies. Cancer biomarkers, indicators that are being produced by the body in spreading tumour cells, play an important role in cancer detection, Dr. Jörg Raach reports
Scientists develop an intelligent knife
Scientists at Imperial College in London, United Kingdom, have developed an ‘intelligent knife’ that instantly informs surgeons whether the tissue they are operating on is cancerous.
Too many tumour boards?
Multidisciplinary tumour boards (MDTs) are widespread in the Netherlands, and ‘they tend to be proliferating lately,’ according to Professor Folkert van Kemenade, Chair of the Pathology department at the VU University Medical Centre in Amsterdam.
The complex science behind microbubbles
At Bracco Suisse SA in Geneva all efforts are dedicated to contrast media for ultrasound scans. During their visit to the firm’s research centre and manufacturing site, Daniela Zimmermann and Ralf Mateblowski met with François Tranquart MD PhD, general manager of the Bracco Suisse research centre, to hear why SonoVue is now Europe’s most popular ultrasound contrast agent, with research…
The 33rd German Society for Senology Congress
Like any other cancer – breast cancer is a highly individual disease, shaped by many factors such as age, health status or genetics. Due to the complex web of molecular pathological processes and resistance mechanisms it is very difficult to select the most effective therapy for each patient.
Re-evaluating the multidisciplinary approach to cancer care
A 2012 study analysing the care of cancer patients in the USA in 138 Veterans’ Administration hospitals (pub: Journal of the National Cancer Institute) questions the effectiveness of tumour board review. The study measured effectiveness by comparing the presence of tumour review boards with stage-specific quality of care and patient outcomes.
Of echoes, triangles and quadrants
Medicine is not immune to prejudices. In the past, the ‘fatty liver’ diagnosis was often accompanied by the hasty conclusion that the problem was surely caused by alcohol abuse.
Treating bladder cancer
Bladder cancer is highly challenging in terms of patient management and medical costs. As the fourth most frequent cancer in men and ninth in women in developed countries, although BC is a common disease it is still under-represented in public awareness and in cancer research .
The role of the immune system in cancer therapy
Apart from tumour immunologists themselves, for a long time oncologists have underestimated the role of the immune system in cancer treatment. Nonetheless, in recent years increasing attention has been given to this aspect of cancer.
Breast surgeons have endorsed ultrasound for decades
Ultrasound may be used during breast conservation surgery, to locate tumour lesions or to place localising wires; it can also guide a lumpectomy and perform a specimen exam to ensure a lesion has been excised and to evaluate surgical margins
Healthcare economics
Research using an analytical health economics model has suggested the current system of screening within the UK’s National Health Service (NHS) is only moderately likely to be cost effective.
A clever(t) fusion for prostate diagnosis
Statistically speaking every fourth older German man suffers from prostate cancer with the mortality rate being 60,000 patients annually
New cooperation in research on ovarian cancer
Sanofi and the Curie Institute, through its Curie-Cancer partnership under the Institut Carnot label, today announce the establishment of a three-year research collaboration to identify new therapeutic targets for the development of treatments for ovarian cancer.
A sharper image with combined PET/MR technology
The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is sending a promising duo into the race against cancer: A new PET/MR system that can combine high-resolution images with functional information to improve cancer diagnosis.
German Cancer Research Center to broaden strategic alliance with Bayer HealthCare
The German Cancer Research Center (DKFZ) and Bayer HealthCare (Bayer) will extend their successful strategic research alliance in search of novel cancer therapeutics by focusing their activities also on the field of immunotherapy.